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Fibroblast growth factor (FGF) 23 produced by bone is a hormone
that decreases serum phosphate (Pi). Reflecting its central role in Pi
control, serum FGF23 is tightly regulated by serum Pi alterations.
FGF23 levels are regulated by the transcriptional event and post-
translational cleavage into inactive fragments before its secretion.
For the latter, O-glycosylation of FGF23 by GALNT3 gene product
prevents the cleavage, leading to an increase in serum FGF23. How-
ever, the molecular basis of Pi sensing in the regulation of serum
FGF23 remains elusive. In this study, we showed that high Pi diet
enhanced the skeletal expression of Galnt3, but not Fgf23, with
expected increases in serum FGF23 and Pi in mice. Galnt3 induction
by high Pi was further observed in osteoblastic UMR 106 cells, and
this was mediated by activation of the extracellular signal-regulated
kinase (ERK) pathway. Through proteomic searches for the up-
stream sensor for high Pi, we identified one subtype of the FGF
receptor (FGFR1c), which was phosphorylated by high Pi in the ab-
sence of FGFs. The mode of unliganded FGFR activation by high Pi
appeared different from that of FGFR bound to a canonical FGFR
ligand (FGF2) when phosphorylation of the FGFR substrate 2α and
ERK was monitored. Finally, we showed that an FGFR inhibitor and
conditional deletion of Fgfr1 in osteoblasts/osteocytes abrogated
high Pi diet-induced increases in serum FGF23 and femoral Galnt3
expression in mice. Thus, these findings uncover an unrecognized
facet of unliganded FGFR function and illustrate a Pi-sensing path-
way involved in regulation of FGF23 production.
phosphate sensor | fibroblast growth factor receptor 1 |
fibroblast growth factor 23
Phosphate (Pi) is a key mineral component in numerous cel-lular events and hard tissues, and the serum Pi level and Pi
balance in the body are well controlled, regardless of excess or
deficient dietary intake. There are several physiological Pi reg-
ulators that maintain a proper balance of Pi in the body, and
dysregulation of this system has been reported to result in dis-
eases associated with deranged mineral and bone metabolism
(1). Among these regulators, fibroblast growth factor (FGF) 23 is
known to play a central role in regulating serum Pi level (2).
FGF23 is one of the FGF family members that mediates a wide range
of biological processes in both developing and adult vertebrates and is
considered an endocrine FGF from its mode of physiological actions
(3). As FGF23 has low affinity for heparan sulfate, it needs α-Klotho
for FGF receptor (FGFR) binding to elicit its biological actions (4).
FGF23 is mainly produced by osteoblasts/osteocytes and reduces
serum Pi by inhibiting proximal tubular Pi reabsorption and sup-
pressing intestinal Pi absorption by decreasing the 1,25-dihydrox-
yvitamin D [1,25(OH)2D] level (5–7). Excessive and deficient FGF23
results in hypo- and hyperphosphatemic diseases, respectively, in-
dicating its significance in Pi control (1). Thus, FGF23 levels are finely
managed by changes in serum Pi levels. FGF23 levels are regulated by
both the expression in bone and posttranslational modification of the
FGF23 protein (8, 9). A portion of the FGF23 protein is pro-
teolytically cleaved into inactive fragments before secretion. We
showed that mucin-type O-linked glycosylation of the FGF23 protein
prevents this cleavage and increases the level of biologically active full-
length FGF23 (10). The GALNT3 gene encodes an enzyme that
initiates the attachment of an O-linked glycan to the FGF23 protein
(11). Although this posttranslational modification of FGF23 appears
pivotal in the regulation of serum FGF23 level, its molecular mech-
anisms in response to serum Pi alternations are unclear.
Here, we found that skeletal Galnt3, but not Fgf23, was induced
with an increase in the serum level of FGF23 in mice fed a high Pi
diet. This Galnt3 induction by high Pi was also observed in an os-
teoblastic cell line, coupled with activation of unliganded FGFR
(FGFR1c). The mode of activation of unliganded FGFR by high Pi
was different from that of FGF2-liganded FGFR, and activated
FGFR led to the extracellular signal-regulated kinase (ERK)
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pathway-mediated induction of Galnt3. These findings illustrate the
unrecognized function of FGFR and uncover the presence of a Pi-
sensing system that posttranslationally regulates FGF23 production.
Results
A High Pi Diet and High Extracellular Pi Increase FGF23 Levels by Preventing
the Processing of FGF23 Protein. Four-week-old male ICR mice were
fed a control (0.6%: CP) and high (1.2%: HP) Pi diet for 2 wk and
were then killed (Fig. 1A). There were no differences in serum urea
nitrogen, creatinine, calcium (Ca) levels and fractional excretion of
Ca (FECa) after 2 wk (SI Appendix, Fig. S1 A–D). The serum Pi
level and fractional excretion of Pi (FEPi) were significantly higher
in the HP group than the CP group (Fig. 1B). The serum con-
centration of full-length biologically active FGF23 in the HP
group was significantly higher than that in the CP group (Fig. 1C).
In contrast to our predictions, HP did not increase Fgf23 mRNA
but increased Galnt3 mRNA in the femur (Fig. 1D). These results
suggest that FGF23 production is regulated through Galnt3 in-
duction in response to dietary HP intake in intact animals.
To further assess these in vivo observations, we tested them in
vitro using the UMR106 osteoblastic cell line. Because there are
no cell lines available that produce FGF23 protein to examine
the effects of high extracellular Pi on the processing of the
FGF23 protein, His-tagged human FGF23 was overexpressed in
UMR106 cells for further in vitro assays. Full-length FGF23 was
detected at higher ratios under high extracellular Pi conditions
(2 mM) than under low Pi conditions (1 mM) when the ratio of
the full-length protein vs. the cleaved C-terminal fragment was
estimated in the culture media of UMR106 cells (Fig. 1E).
Galnt3 mRNA expression was also enhanced under high extra-
cellular Pi in a dose-dependent manner in the UMR106 cells,
and Galnt3 induction peaked at 48 h (Fig. 1 F and G). High
extracellular Pi also enhanced the expression of the GalNAc-
T3 protein encoded by Galnt3 (Fig. 1H). Furthermore, when
human GALNT3 and FGF23 were overexpressed, the ratio of
the full-length protein vs. the C-terminal fragment of the
FGF23 protein was increased (Fig. 1I). These results indicate
that high extracellular Pi increases Galnt3 expression and
thereby prevents the processing of FGF23 protein.
It was previously reported that the processing of FGF23 pro-
tein is mediated by protease like Furin and the processing is fur-
ther enhanced by phosphorylation of FGF23 protein by a kinase
[family with sequence similarity 20, member C (FAM20C)] (8).
Therefore, the roles of these two factors in the Pi response in
FGF23 processing were assessed. High phosphate diet and high
extracellular phosphate did not change expression of Furin in the
femur and UMR106 cells (SI Appendix, Fig. S2 A and B), while
Fam20c expression was enhanced by high phosphate diet and high
Fig. 1. Pi increases FGF23 levels by preventing the
processing of the FGF23 protein via the gene prod-
uct of Galnt3. (A) Schema of the experimental pro-
cedure. (B and C) Serum Pi, FEPi (B) and serum full-
length FGF23 (C) in mice fed a CP or HP diet for
2 wk. (D) Fgf23 andGalnt3mRNA expression in femurs
of mice fed a CP or HP diet for 2 wk. (E) Immuno-
blotting with an antibody to FGF23 secreted into the
media from UMR106 cells overexpressing His-tagged
human FGF23 after immunoprecipitation with anti-
His-tag antibody under 1 or 2 mM Pi for 48 h (Left).
The Right shows the quantified ratio of full-length
protein/the C-terminal fragment of FGF23 protein.
(F) Galnt3 mRNA expression under various extracellu-
lar Pi concentrations for 48 h in UMR106 cells. (G)
Galnt3mRNA expression with 5mMPi in UMR106 cells
was measured at the indicated times. (H) Immuno-
blotting with an antibody to GalNAc-T3 encoded by
Galnt3 from the lysates of UMR106 cells under 1 or
5 mM Pi for 48 h. (I) Immunoblotting with an antibody
to FGF23 secreted into the media from UMR106 cells
overexpressing human GALNT3 together with His-
tagged FGF23 under 1 mM Pi for 48 h (Left). The
Right shows the quantified ratio of full-length/C-
terminal fragment of FGF23 protein. Data represent
the mean ± SEM. (B–D) n = 19 mice per group; *P <
0.05 by Student’s t test; NS, not significant. (E and I)
n = 3 per group; *P < 0.05 by Student’s t test. (F and G)
n = 3 per group; *P < 0.05 by ANOVA with a post hoc
Dunnett’s test compared with 1 mM of extracellular Pi
(F) or 0 h (G). (E, H, and I) Data are presented as a
representative image.
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extracellular phosphate (SI Appendix, Fig. S2 C and D). From the
observation that the serum full-length FGF23 was increased by
high phosphate diet, the roles of FAM20C and Furin in the Pi
response appeared marginal.
Collecting these findings together, we assumed that that Galnt3,
but not Fgf23, is a Pi-responsive gene and that the induction of
Galnt3 expression by high extracellular Pi must be mediated by a
Pi-sensing mechanism. Therefore, we used Galnt3 expression as a
marker to explore the Pi-sensing mechanism in bone.
High Extracellular Pi Induces Galnt3 Expression Through Activation of
the ERK Pathway. We next addressed the mechanism by which
extracellular Pi induces Galnt3 expression. As Pi level alterations
did not affect the half-life of Galnt3 mRNA (SI Appendix, Fig.
S3), we reasoned that Galnt3 is induced by Pi at the transcrip-
tional level. However, as Galnt3 induction by Pi peaked at 48 h
(Fig. 1G), we presumed the involvement of intermediary mole-
cules. To address this point, we performed a DNA microarray
analysis using UMR106 cells with or without high Pi treatment
for 6 h. We focused on 17 genes that appeared inducible at the
transcriptional level by high Pi (Fig. 2A), and the ERK pathway
was selected (Fig. 2B). Among the members of this pathway,
three genes encoding transcription factors related to the ERK
pathway, early growth response 1 (Egr1), ETS variant 4 (Etv4), and
ETS variant 5 (Etv5), were further identified because the ERK
pathway was previously reported to be activated by high Pi (12,
13). Indeed, all three genes were induced by high Pi (Fig. 2C),
while the addition of sulfate, which increased the osmotic pres-
sure to a similar extent as Pi, did not induce these genes. Most
notably, silencing of Egr1 and Etv5 by small interfering RNA
(siRNA) aborted the induction of Galnt3 by high Pi (Fig. 2D),
confirming the significance of these transcriptional activators in
Galnt3 induction by high Pi.
We then asked if high Pi activates the ERK pathway by im-
munoblotting activated ERK1/2 in UMR106 cells. Activation of
ERK1/2 (the phosphorylated form) was induced by high Pi as well
as a known activator (FGF2) in the UMR106 cells (Fig. 2E). High
extracellular Pi induced the phosphorylation of ERK1/2 in a dose-
dependent manner, as shown by an immunoblotting assay (Fig.
2F) or a serum response element (SRE) luciferase reporter assay
designed to monitor the activity of the ERK signaling pathway
(Fig. 2G). Furthermore, the ERK kinase (MEK) 1/2 inhibitor
U0126 attenuated the effect of high Pi on Galnt3 induction (Fig.
2H), further supporting our findings that high Pi induces Galnt3
through activation of the ERK pathway. However, high Pi did not
induce ERK phosphorylation in other nonbone rat cell lines (the
L6 myoblastic cell line and the JCT19 fibroblastic cell line) (SI
Appendix, Fig. S4 A and B). Since it is still unclear how the high Pi
signal results in ERK activation, we further searched for an up-
stream factor that activates the ERK pathway by high Pi.
Activation of the FGF Receptor by High Pi Induces Galnt3. Since the
ERK pathway is activated as a downstream signal inducer of
activated transmembrane receptors in general, we focused on
receptor tyrosine kinases (RTKs) (14). As RTKs are phosphor-
ylated at tyrosine residues upon activation, phosphorylated ty-
rosine residues were searched by a proteomic approach. From
lysates of UMR106 cells treated with high Pi, tryptic peptides
were immunopurified by an antiphosphotyrosine antibody and
subjected to LC-MS/MS analysis (Fig. 3A). Fig. 3B shows the
results of the identification and label-free quantification of the
top 20 peptides with phosphotyrosine in the order of fold in-
crease by high Pi (the whole data set is shown in SI Appendix,
Table S1). ERK1 and ERK2, encoded by Mapk3 and Mapk1,
respectively, were the top two proteins. This analysis led us to
identify FGFR1 as the only RTK and a phosphorylation target of
high Pi. The identification of FGFR1 is supported by previous
reports suggesting the involvement of FGFR in cellular re-
sponses to extracellular Pi (12, 15). Six tyrosine residues, tyro-
sines 653, 583, 463, 766, 585, and 654, are known to be sequentially
phosphorylated in this order upon the FGFR1 activation (16, 17).
In addition, phosphorylation of two tyrosine residues, 653 and 654,
is important for generating an activation loop and dramatically
increasing tyrosine kinase activity of FGFR1 (3). In our study,
there were two types of FGFR1 peptides, one with phosphorylated
tyrosines 583 and 585 and the other with phosphorylated tyrosines
653 and 654, suggesting that FGFR1 was activated by Pi (Fig. 3C).
We further performed targeted quantification using parallel re-
action monitoring (PRM), which enabled highly specific and ac-
curate quantification of multiple peptides simultaneously (whole
dataset is shown in SI Appendix, Table S2). The phosphorylated
form of FGFR1 at tyrosines 653 and 654 was significantly in-
creased approximately threefold by high Pi (Fig. 3 D and E).
However, the protein level of the phosphorylated FGFR1 at ty-
rosines 583 and 585 was increased, but its increase was statistically
not significant (SI Appendix, Fig. S5 A and B). FGF2, a canonical
FGFR ligand that induces FGFR phosphorylation, induced
phosphorylation of tyrosines 653 and 654, as expected, but this
change was more robust than that of high Pi (Fig. 3E). The results
of quantification of other peptides by PRM analysis are shown in
SI Appendix, Fig. S5 C and D. The protein level of ERK2, which is
encoded by Mapk1, with phosphorylated threonine 183 and tyro-
sine 185 was increased by both high Pi and FGF2 (SI Appendix,
Fig. S5C). FGFR is known to activate several intracellular signal-
ing molecules, such as phosphoinositide 3-kinase (PI3K)-protein
kinase B (Akt) and phospholipase Cγ (PLCγ)-calcineurin, in ad-
dition to ERK (18). However, unlike FGF2, high Pi was not ef-
fective in increasing the protein level of phosphorylated PLCγ (SI
Appendix, Fig. S5D). Expectedly, the calcineurin inhibitor
FK506 showed no effect on Galnt3 induction by high Pi (SI Ap-
pendix, Fig. S6A). Likewise, high Pi did not induce phosphoryla-
tion of Akt (SI Appendix, Fig. S6B), and PI3K inhibitor
wortmannin had no effect on Galnt3 induction (SI Appendix, Fig.
S6C). These results suggest that high Pi specifically activates the
ERK pathway downstream of FGFR1.
UMR106 cells endogenously express only FGFR1c (Fig. 3F),
one of the two FGFR1 subtypes (FGFR1b and FGFR1c) (3), at a
low protein level. When Fgfr1c was overexpressed in UMR106
cells, increased phosphorylation of FGFR1c was observed by im-
munoblotting with an antibody to phosphorylated FGFR under
high extracellular Pi (Fig. 3G). The FGFR inhibitor PD173074
aborted both Galnt3 induction and ERK phosphorylation by high
Pi (Fig. 3 H and I). Similarly, silencing of Fgfr1 also blunted the
enhanced expression of Galnt3 and the enhanced phosphorylation
of ERK by high Pi (SI Appendix, Fig. S7 A and B).
Galnt3 Induction Is Mediated by Activated FGFR with High Pi but Not
a Canonical FGF Receptor Ligand. As high Pi potently induced
Galnt3 via the activated FGF receptor, we tested whether a ca-
nonical FGFR ligand was also effective in inducing Galnt3.
While one of the canonical FGFR ligands, FGF2, activated the
ERK pathway (Fig. 2E), as expected from previous reports,
FGF2 tended to be inactive in Galnt3 induction (Fig. 4A). To
explore the molecular basis of the difference in FGFR activation
between high Pi and FGF2, we further assessed the phosphory-
lation sites of FGFR substrate 2α (FRS2α), which is known to be
a phosphorylation substrate of activated FGFR and is necessary
for the activation of the downstream ERK pathway (18, 19).
Consistent with previous findings, tyrosines 196 and 436 of
FRS2α were phosphorylated by FGF2 stimulation. However,
phosphorylation by high Pi stimulation was evident only at ty-
rosine 196 (Fig. 4B). When ERK activation was monitored in a
time course, activation of ERK by high Pi was transient, unlike
that by FGF2 (Fig. 4C). In addition, the time course of the ac-
tivation of FRS2α differed between high Pi and FGF2 (Fig. 4D).
Thus, these findings elucidate the FGFR activation by Pi in
which the Pi signal is transmitted into ERK pathway stimulation,
leading to Galnt3 induction.
An FGFR Inhibitor Attenuates Galnt3 Up-Regulation by a High Pi Diet
in Intact Animals.We addressed whether activated the FGFR-ERK
pathway indeed transmits extracellular Pi signals into Galnt3
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Fig. 2. The up-regulation of Galnt3 by Pi requires activation of the ERK pathway and induction of Egr1 and Etv5. (A and B) The results of DNA microarray
analysis in a volcano plot using UMR106 cells with or without 5 mM Pi treatment for 6 h (A, Left). The table shows 17 genes significantly induced by Pi (A,
Right). These included genes for several transcription factors, ERK pathway components, and bone-related proteins (B). (C) Egr1, Etv4, and Etv5 mRNA ex-
pression by 5 mM Pi or 5 mM sulfate for 6 h evaluated by qPCR. (D) Galnt3 mRNA expression by 5 mM Pi for 12 h compared with 1 mM Pi under siRNA-
mediated silencing of Egr1, Etv4, and Etv5. (E and F) Immunoblotting with an antibody to phosphorylated ERK1/2 from the lysates of UMR106 cells treated
with 1 or 5 mM Pi, 100 ng/mL FGF2, or 5 mM sulfate for 15 min (E) or treated with 1, 3, or 5 mM Pi (F). (G) ERK activation under various extracellular Pi
concentrations for 24 h evaluated by SRE luciferase assays. (H) Galnt3mRNA expression by 5 mM Pi for 48 h with or without the MEK1/2 inhibitor U0126. Data
represent the mean ± SEM. (C, D, and G) n = 3 per group; *P < 0.05 by ANOVA with a post hoc Tukey’s test (C and D) or with a post hoc Dunnett’s test
compared with 1 mM of extracellular Pi (G). (E and F) Data are presented as a representative image. (H) n = 3 per group; *P < 0.05 compared with 1 mM Pi
without U0126, #P < 0.05 compared with 1 mM Pi with U0126, †P < 0.05 compared with 5 mM Pi with U0126 cells by ANOVA with a post hoc Tukey’s test.
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Fig. 3. FGFR1c functions as a Pi-sensing mechanism. (A) Schematic diagram of the proteomics workflow. UMR106 cells were treated with 5 mM Pi or 100 ng/mL
FGF2 for 15 min. After immunoaffinity purification with an anti-phosphotyrosine antibody, each sample was analyzed by LC-MS/MS. Three biological
replicates for each sample were prepared, and an accurate amount of the proteins was measured by targeted MS. (B) The results of identification and label-
free quantification of the top 20 peptides with phosphotyrosine in the order of fold increase induced by high Pi. (C) Phosphorylation of tyrosines 583 and
585 and tyrosines 653 and 654 of FGFR1 was demonstrated by the MS/MS spectrum of the m/z 921.38534 and 497.87357 ions in tryptic phophopeptides,
respectively. Experiments were independently repeated two times with similar results. (D) Extracted ion chromatograms of transitions of the FGFR1 peptide
with phosphorylated tyrosines 653 and 654. Each peptide in three independently prepared samples was analyzed by targeted MS using the PRM method. (E)
The amount of FGFR1 peptide with phosphorylated tyrosines 653 and 654 normalized to the amount of cyclin-dependent kinase 2 (CDK2) peptide with
phosphorylated tyrosine 15 in the same sample. (F) The expression level of FGFR1 subtypes evaluated by qPCR. (G) Immunoblotting with phosphorylated FGFR
(tyrosine 653/654) from the lysates of UMR106 cells overexpressing Fgfr1c under 1 or 5 mM Pi for 15 min. (H) Galnt3 mRNA expression with 1 or 5 mM Pi for
48 h with or without PD173074. (I) Immunoblotting with an antibody to phosphorylated ERK1/2 from the lysates of UMR106 cells under 1 or 5 mM Pi, with or
without PD173074 for 15 min. Data represent the mean ± SEM. (E) n = 3 per group; *P < 0.05 by ANOVA with a post hoc Tukey’s test. (F) n = 3 per group. ND,
not detected. (G and I) Data are presented as a representative image. (H) n = 3 per group; *P < 0.05 compared with 1 mM Pi without PD173074, #P <
0.05 compared with 1 mM Pi with PD173074, †P < 0.05 compared with 5 mM Pi with PD173074 by ANOVA with a post hoc Tukey’s test.
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induction in intact animals. Enhanced phosphorylation of ERK in
the femur by a high phosphate diet was visible in the whole tissue
extracts by immunoblotting (SI Appendix, Fig. S8), but neither
phosphorylation of FRS2α nor GalNAc-T3 was detectable, pre-
sumably due to low protein expression levels. Then, an FGFR
inhibitor, NVP-BGJ398, was given to mice fed a CP or HP diet for
2 wk (Fig. 5A). Except for serum Pi and FEPi (Fig. 5B), the levels
of the other serum components (Fig. 5C) were unchanged by the
Pi dietary contents. As a note, the baseline Pi level in mice in this
experiment was lower than that in the previous experiment
(compare Fig. 1B and Fig. 5B). Although the serum Pi level was
significantly higher in mice fed an HP diet than in mice fed a CP
diet under NVP-BGJ398 treatment, neither the serum level of
full-length FGF23 nor Galnt3mRNA in the femur showed a clear
increase (compare Fig. 5D with Fig. 1C for serum FGF23 level,
and Fig. 5E with Fig. 1D for Galnt3 in the femur), confirming the
proposed function of FGFR in Galnt3 induction.
A Selective Ablation of Fgfr1 in Osteoblasts/Osteocytes Aborts Galnt3
Up-Regulation by a High Pi Diet. We have selectively ablated Fgfr1
(Fgfr1-cKO) by crossing Osteocalcin (Ocn)-Cre mice (20) with
floxed Fgfr1 mice (21) (Fig. 6A). The expression of Fgfr1 mRNA
in the femur was much lower in Fgfr1-cKO mice (Fgfr1fl/fl;
OcnCre/+) than that in control mice (Fgfr1fl/fl; Ocn+/+) (Fig. 6B).
The serum Pi level was significantly higher not only in control and
Fgfr1-cKO mice fed a HP diet, but also in Fgfr1-cKO mice fed a
CP diet compared with that in control mice fed a CP diet (Fig.
6C). The increase of serum full-length FGF23 was blunted in
Fgfr1-cKO mice fed a HP diet (Fig. 6D). Although there was no
significant difference in Fgf23 mRNA expression, the enhance-
ment ofGalnt3mRNA expression by a HP diet in Fgfr1-cKO mice
was attenuated (Fig. 6E). These results again support the impor-
tance of FGFR1 in the regulation of Galnt3 expression by Pi.
Discussion
The production of active FGF23 is regulated in response to al-
terations in serum Pi level, although the molecular basis of Pi
sensing in FGF23 production is unclear. In the present study, we
found that a high Pi diet in mice enhanced the expression of
Galnt3 but not Fgf23 in the femur with an increase in the serum
level of full-length active FGF23 (Fig. 1 C and D). As the serum
level of active full-length FGF23 was up-regulated, O-glycosylation
of FGF23 by the Galnt3 product appeared to be enhanced. To
further address the mechanism of Galnt3 induction by high Pi, we
used an in vitro osteoblastic UMR106 cell culture model. By
proteomic analysis and gene expression array analysis, high ex-
tracellular Pi was shown to activate unliganded FGFR1c, leading
to Galnt3 induction via the ERK pathway, at least in part through
two transcriptional activators (EGR1 and ETV5) (Fig. 7). How-
ever, when phosphorylation of downstream FRS2α and ERK was
monitored, the mode of FGFR1c activation by high Pi was dif-
ferent from that by FGF2 (Fig. 4 B–D). Thus, the present findings
illustrate a Pi-sensing pathway through FGFR1c in the regulation
of FGF23 production. Finally, we showed that an FGFR inhibitor
or selective deletion of Fgfr1 in osteoblasts/osteocytes abrogated
high Pi diet-induced increases in serum concentration of active
full-length FGF23 and femoral Galnt3 expression in mice (Figs. 5
D and E and 6 D and E). We, therefore, could suggest the sig-
nificance of FGFR1 in a Pi-sensing mechanism in vivo. This idea is
further supported by previous findings that some activating mu-
tations in FGFR1 cause high FGF23 levels and hypophosphatemia
in patients with osteoglophonic dysplasia (22). Pi has been
reported to be involved in several other biological responses in
addition to regulating FGF23 levels, such as PTH secretion,
chondrocyte apoptosis, and the development of vascular diseases
(23–25). In this respect, it is important to investigate whether
FGFR1c also senses high Pi in these responses.
Fig. 4. Pi and FGF2 differentially activate the
FGFR1-FRS2α-ERK pathway. (A) Galnt3 mRNA ex-
pression under 1 or 5 mM Pi or 100 ng/mL FGF2 for
48 h. (B) Immunoblotting with phosphorylated
FRS2α at tyrosine 196 or tyrosine 436 from the ly-
sates of UMR106 cells under 1 or 5 mM Pi, 100 ng/mL
FGF2, or 5 mM sulfate for 15 min. (C and D) The time
course of ERK1/2 phosphorylation (C, Left) or FRS2α
phosphorylation at Tyr196 (D, Left) by 100 ng/mL
FGF2 or 5 mM Pi. The Right shows the phosphory-
lated ERK1/2 (C, Right) or phosphorylated FRS2α
levels (D, Right). Data represent the mean ± SEM. (A)
n = 3 per group; *P < 0.05 by ANOVA with a post hoc
Tukey’s test. (B–D) Data are presented as a repre-
sentative image.
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Several humoral factors such as parathyroid hormone (PTH) and
1,25(OH)2D have been shown to control FGF23 expression and
FGF23 levels (26–28). PTH was already reported to suppress Galnt3
expression (25), but the high phosphate diet rather increased PTH
(SI Appendix, Fig. S9A). Furthermore, 1,25(OH)2D3 enhanced
Fgf23 expression in UMR106 cells, as already reported (SI Ap-
pendix, Fig. S9B) (26), but 1,25(OH)2D3 had no effect on Galnt3
expression in UMR106 cells (SI Appendix, Fig. S9C). Therefore,
we presume that PTH and 1,25(OH)2D are unlikely to facilitate
increases in Galnt3 expression and serum level of full-length
FGF23 by high phosphate.
Pi sensing in terms of Galnt3 induction was observed in the
intact femur, and ERK activation for Galnt3 induction was evi-
dent only in the osteoblastic cell line but not in the other cell
lines derived from nonbone tissues (SI Appendix, Fig. S4 A and
B). It appears unlikely that the lack of Pi sensing in ERK acti-
vation in the other cell line is simply due to the absence of
FGFR1c since we observed that overexpression of FGFR1c in
that nonosteoblastic cell line was still not capable of activating
the ERK pathway (SI Appendix, Fig. S4C). It is more likely that
an unknown factor(s) in osteoblastic cells facilitates Pi sensing to
stimulate the ERK pathway for Galnt3 induction through
FGFR1c. This unknown factor(s) might account for the osteo-
blastic cell type-specific sensing of high Pi for FGFR1c activa-
tion. As FGFR1c isoforms preferentially interact with FGFR
ligands that are secreted from epithelial tissues (18), the activity
of FGFR ligands secreted from epithelial cells might be modu-
lated when FGFR1c expression in mesenchymal lineage cells is
activated by local or serum Pi levels. As chondrocytes, muscle
cells and adipocytes are also differentiated from mesenchymal
stem cells, such as osteoblasts, FGFR1c isoforms in these cell
types might be activated by high Pi. This possibility could be
tested by other assay systems to evaluate FGF actions, such as
those in developing embryos of animal models.
In this study, EGR1 and ETV5 were identified as transcrip-
tional activators that induce Galnt3 expression when FGFR1c
was activated by high Pi (Fig. 2D). However, it is still unclear at
this stage if other transcription factors are also required to ac-
tivate the Galnt3 promoter. In a previous report concerning the
promoter function ofGALNT3 in a human breast cancer cell line
(MCF-7) (29), only several binding sites for transcriptional ac-
tivators such as SP1 and AP2 were identified in the promoter
region. Thus, to date, no information on the GALNT3 promoter
function in Pi sensing is available. In this regard, it is interesting
to delineate and assess the binding sites for EGR1 and ETV5 in
the GALNT3 promoter as an enhancer to address the impact of
EGR1 and ETV5 on GALNT3 induction by high Pi. It is also
possible that another signaling pathway(s) might facilitate the
promoter function of Galnt3, such as the ERK pathway, as
shown in this study. In terms of a screening system to sense ex-
tracellular Pi as well as other extracellular stimuli, the promoters
of Galnt3 may be useful in further studies.
FGFR is known to form either homodimers to facilitate binding
of paracrine FGFs or dimers with coreceptors, such as Klothos, for
binding of endocrine FGFs such as FGF23 (18). Phosphorylation
of FGFRs is known to be coupled with FGFR activation by FGFR
ligand binding, while the strength of FGFR activation is different
depending on FGFR ligand types (30). Although we found that
unliganded FGFR1c was activated by high Pi, the activation pro-
cess of FGFR1c still remains elusive. On the other hand, the di-
merization of the unliganded FGFR model has been proposed by
several reports (30–32). For dimerization of unliganded FGFR at
the cell surface, the transmembrane (TM) domain, rather than
the extracellular and the intracellular tyrosine kinase domains, is
Fig. 5. FGFR functions as a Pi sensor in vivo. (A)
Schema of the experimental procedure. (B–D) Serum
Pi, FEPi (B), serum Ca, FECa, serum urea nitrogen, se-
rum creatinine (C), and serum full-length FGF23 (D)
in mice fed a CP or HP diet for 2 wk under the ad-
ministration of NVP-BGJ398. (E) Galnt3 mRNA ex-
pression in the femurs of mice fed a CP or HP diet for
2 wk under the administration of NVP-BGJ398 was
evaluated by qPCR. Data represent the mean ± SEM.
(B–E) n = 4 mice per group; *P < 0.05 by Student’s
t test; NS, not significant.
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known to be pivotal (30, 31). High-resolution crystal structures of
FGFR TM domains have already provided a view of the whole
TM domain as composed of complement associations of α-helix
loops on each domain (33). The significance of the TM domain for
receptor activation is further implicated by the clinical observa-
tions by detecting genetic mutations in the TM and its adjacent
domains of FGFR1 in patients with osteoglophonic dysplasia, who
suffer from high FGF23 levels and hypophosphatemia by hyper-
activation of the FGFR-mediated signaling. In addition, by an
approach using the Förster resonance energy transfer (FRET)-
based technique (31), FGFR1 with these mutations was shown
to be prone to form FGFR1 dimerization compared with intact
FGFR1 in the absence of canonical FGFR1 ligands. In the present
study, high Pi was found to induce phosphorylation at the specific
residues in the intracellular domain of FGFR1c, presumably
resulting in an alteration of FGFR1c protein structure such as
stabilizing interaction between the TM domains. Thus we assume
at this stage, based on our present findings and these past reports,
that FGFR1c activation by high Pi is mediated by potentiation of
dimerization of unliganded FGFR1c by receptor phosphorylation.
We observed activation of FGFR1c by high Pi and charac-
terized a cascade to transmit high Pi signals into Galnt3 in-
duction. Furthermore, we identified the ERK pathway as an
FGFR1c downstream signaling pathway among several known
downstream pathways activated by FGFR (18), although we
cannot exclude the possibility that the downstream signaling
pathways other than AKT and PLCγ may be stimulated by ac-
tivated FGFR1c by high Pi. Further biochemical assays revealed
that the mode of FGFR1c activation by high Pi is not identical to
that by the FGFR canonical ligand (FGF2). These findings suggest
the possibility that the structural form of activated FGFR1c induced
by high Pi is different from that by canonical ligands (18) and hence
interacts with unknown factors located on the cell membrane and/or
in the cytosol, as FGF2 failed to induceGalnt3 (Fig. 4A), regardless
of activation of the same downstream ERK pathway. Further dis-
section of the molecular basis of FGFR1c activation by high Pi is
clearly required for a better understanding of Pi sensing for
FGF23 production. Recent studies indicated the involvement of
sodium-dependent Pi transporter PiT2 encoded by Slc20a2 in the
regulation of FGF23 by phosphate (34, 35). However, a high
Fig. 6. Responses to high Pi diet in Fgfr1-cKO mice.
(A) Genomic structure of the floxed and deleted
Fgfr1 alleles. (B) Fgfr1 mRNA expression in the fe-
murs of 8-wk-old male control (Fgfr1fl/fl; Ocn+/+) and
Fgfr1-cKO (Fgfr1fl/fl; OcnCre/+) mice. (C and D) Serum
Pi (C) and serum full-length FGF23 (D) in control and
Fgfr1-cKO mice fed a CP or HP diet for 10 d. (E) Fgf23
and Galnt3 mRNA expression in the femurs of con-
trol and Fgfr1-cKO mice fed a CP or HP diet for 10 d
were evaluated by qPCR. Data represent the mean ±
SEM. (B) n = 4 mice per group; *P < 0.05 by Student’s
t test. (C–E) n = 4–7 mice per group; *P < 0.05 com-
pared with control mice fed a CP diet, #P <
0.05 compared with Fgfr1-cKO mice fed a CP diet,
†P < 0.05 compared with Fgfr1-cKO mice fed a HP
diet by ANOVA with a post hoc Tukey’s test.
Takashi et al. PNAS | June 4, 2019 | vol. 116 | no. 23 | 11425
M
ED
IC
A
L
SC
IE
N
CE
S
phosphate diet did not induce the expression of Slc20a2 in the fe-
mur (SI Appendix, Fig. S10A). In addition, silencing Slc20a2 in
UMR106 cells did not suppress the induction of Galnt3 by high
extracellular phosphate (SI Appendix, Fig. S10 B and C).
In conclusion, our results demonstrate the importance of
posttranslational modification of the FGF23 protein in the reg-
ulation of FGF23 production. These observations are corrobo-
rated by the fact that inactivating mutations in GALNT3 cause
hyperphosphatemic familial tumoral calcinosis owing to im-
paired actions of FGF23 by enhanced proteolytic processing of
its protein (36).
Materials and Methods
Materials. Stimulation by Pi was performed using 0.1 M Pi buffer, pH 7.4,
containing Na2HPO4 and NaH2PO4. FGF2 was purchased from R&D Systems.
U0126, wortmannin, and PD1703074 were purchased fromWako. FK506 was
purchased from Sigma-Aldrich. Calcitriol [1,25(OH)2D3] was purchased
from Carbosynth.
Mice and Treatment. All animal procedures were approved by the Animal
Research Committee at Tokushima University. ICR mice were purchased from
Japan SLC. Four-week-oldmale ICRmicewere fed a CP diet containing 0.6%Pi
(16012703, Research Diets) or a HP diet containing 1.2% Pi (11101203, Re-
search Diets) for 2 wk. Each diet included 0.5% Ca, and there were no dif-
ferences in any other component. NVP-BGJ398 (Selleckchem) was formulated
as a suspension in PEG300/D5W (2:1, vol/vol) and orally administered daily for
2 wk at 15 mg/kg (37). We generated conditional knockout mice for Fgfr1
(Fgfr1-cKO) using Ocn-Cre mice. Ocn-Cre mice were originally purchased
from The Jackson Laboratory. The floxed Fgfr1 mice were obtained from
Juha Partanen, University of Helsinki, Helsinki, Finland (21). The floxed Fgfr1
mice and Ocn-Cre mice were maintained in C57BL/6N background. The floxed
Fgfr1 allele was detected by PCR with specific primers 5′-AATAGGTCCCTC-
GACGGTATC-3′ and 5′-CTGGGTCAGTGTGGACAGTGT-3′. The wild-type Fgfr1
allele was detected with primers 5′-CCCCATCCCATTTCCTTACCT-3′ and 5′-
TTCTGGTGTGTCTGAAAACAGCT-3′. Ocn-Cre transgenes were detected with
specific primers 5′-CAAATAGCCCTGGCAGATTC-3′ and 5′-TGATACAAGGGA-
CATCTTCC-3′. Eight-week-old male Fgfr1-CKO mice were fed a CP diet con-
taining 0.6% Pi or a HP diet containing 1.2% Pi for 10 d.
Animals were killed and blood was collected by cardiac puncture. Before
killing, urine samples were collected using metabolic cages. The femur was
removed, and the epiphysis and adherent soft tissues were cut away. Bone
marrow was flushed with saline. The cleaned femur was rapidly frozen in
liquid nitrogen.
Cell Culture and in Vitro Experiments. The UMR106 rat osteosarcoma cell line
was obtained from ATCC. UMR106 cells were cultured in DMEM (Wako) sup-
plementedwith 10% FBS (Mediatech) and penicillin/streptomycin/amphotericin
B (Wako). Cell cultures were maintained at 37 °C with 5%CO2. For experiments
involving stimulation by several reagents, UMR106 cells were plated at
200,000 per well in 12-well plates in DMEMwith 10% FBS and antibiotics. After
reaching 80% confluence, cells were cultured in medium with 1% FBS and
stimulated with each reagent. At 50% confluence, UMR106 cells were transfected
with expression vectors using FuGENE HD Transfection Reagent (Promega).
Full-Length FGF23 and Intact PTH Measurements. Full-length FGF23 concen-
trationsweremeasured by the FGF23 ELISA kit (Kainos) (2, 38). Serum intact PTH
concentrations were measured by the mouse PTH 1-84 ELISA kit (Immutopics).
RNA Analysis. Collected femur samples were soaked in RNAiso Plus (TaKaRa)
and homogenized with TissueLyser II (Qiagen). Total RNA from the ho-
mogenates and UMR106 cells were extracted with a NucleoSpin RNA system
(Machrey-Nagel). First-strand cDNA was synthesized from total RNA with
PrimeScript RT Master Mix (TaKaRa). RT-qPCR was performed using FastStart
Essential DNA Green Master (Roche) and LightCycler 96 System (Roche). The
gene expression level was normalized to that of glyceraldehyde-3-phosphate
dehydrogenase (Gapdh).
Immunoblot Analysis. UMR106 cells were lysed in RIPA buffer (50 mM Hepes,
150 mM NaCl, 1% Nonidet P-40, 0.5% Na-deoxycholate, 0.1% SDS, 1 mM
EDTA) with Complete Mini Protease Inhibitor Mixture (Roche). For immu-
noblot analysis of phosphorylated proteins, RIPA buffer was also supple-
mented with PhosSTOP (Roche) to inhibit phosphatase activity. His-tagged
human FGF23 protein secreted into culture media of UMR106 cells was pu-
rified using the MagneHis Protein Purification System (Promega). Frozen
femur samples were subjected to protein extraction using drill homogenizer.
SDS/PAGE was performed using 10% polyacrylamide gels. After electro-
phoresis, proteins were transferred to polyvinylidene difluoride (PVDF)
membranes. Membranes were incubated with anti-FGF23 C-terminal anti-
body (a gift from Kyowa Hakko Kirin Co., 1:2,000), anti-GalNAc-T3 antibody
(Aviva Systems Biology, 1:1,000), anti-phospho-ERK1/2 (Thr202/Tyr204) an-
tibody (Cell Signaling Technology, 1:1,666), anti-ERK1/2 antibody (Cell Sig-
naling Technology, 1:4,000), anti-phospho-Akt (Ser473) antibody (Cell
Signaling Technology, 1:2,000), anti-Akt antibody (Cell Signaling Technology,
1:1,000), anti-phospho-FGFR (Tyr653/654) antibody (Cell Signaling Technol-
ogy, 1:1,000), anti-FGFR1 antibody (Cell Signaling Technology, 1:1,000), anti-
phospho-FRS2α (Tyr196) antibody (Cell Signaling Technology, 1:2,000), anti-
phospho-FRS2α (Tyr436) antibody (Cell Signaling Technology, 1:2,000), and
anti-α-Tubulin antibody (Sigma-Aldrich, 1:4,000) followed by horseradish
peroxidase-conjugated secondary antibodies. Protein bands were visualized
with Clarity Western ECL Substrate (Bio-Rad) and the ChemiDoc Touch Im-
aging System (Bio-Rad). Image Lab software (Bio-Rad) was used to quantify
the intensity of bands.
DNA Microarray Analysis. DNA microarray analysis was performed using
UMR106 cells with or without 5 mM Pi treatment for 6 h. Gene expression was
tested using SurePrint G3 Rat GE Ver2.0 8 × 60K (Agilent Technologies). Data
were analyzed using GeneSpring software (Agilent Technologies) and normal-
ized. The statistical analysis was performed using Mann–Whitney unpaired tests.
Gene Silencing. Duplexed siRNA of each target gene (Egr1, Etv4, Etv5, Fgfr1,
and Slc20a2) and its scrambled siRNA as a negative control were designed
and purchased from Bioneer. The siRNA oligonucleotides were transfected
using Lipofectamine RNAiMAX reagent (Invitrogen).
Luciferase Reporter Assays. The activation of the ERK signaling pathway was
analyzed using a pGL4.33 vector that contained a SRE (Promega). Luciferase
activities were measured with a Dual-Luciferase Reporter Assay System
(Promega) and a GloMax Discover Multimode Microplate Reader (Promega).
As a reference to normalize the transfection efficiency, the pRL-TK vector
(Promega) was cotransfected in all experiments.
Identification and Quantification of Tyrosine-Phosphorylated Peptides by LC-
MS/MS Analysis. A previously described method was used with some modi-
fications (39–41). Unstimulated UMR106 cells or cells stimulated with 5 mM
Pi or 100 ng/mL FGF2 for 15 min were lysed in buffer containing 6 M
guanidine-HCl, 100 mM Tris·HCl, pH 8.0, 2 mM DTT, and PhosSTOP. The ly-
sates were sonicated and cleared by centrifugation at 15,000 × g at 4 °C for
15 min. Proteins (each 1.0 mg) were reduced with 5 mM DTT for 30 min and
then alkylated with 27.5 mM iodoacetamide for 30 min in the dark. After
methanol/chloroform precipitation, proteins were dissolved in 100 μL of
0.1% RapiGest SF (Waters) in 50 mM triethylammonium bicarbonate buffer.
The proteins were digested with 10 μg of trypsin (MS-Grade, Thermo Fisher
Scientific). After 16 h at 37 °C, tyrosine-phosphorylated peptides were enriched
Fig. 7. Proposed model of the Pi-sensing mechanism in bone cells. The
detailed activation mechanism of FGFR1c is still unclear. EGR1 and ETV5, as
transcription factors, are necessary for the induction of Galnt3 by Pi; how-
ever, other unknown factors may also be required to induce Galnt3.
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using the PTMScan Phospho-Tyrosine Rabbit mAb (P-Tyr-1000) kit (Cell Sig-
naling Technology) in the presence of 1 mg/mL Pefabloc SC (Sigma-Aldrich) in
accordance with the manufacturer’s instructions. Peptides were eluted with
150 μL of 60% ACN/0.1% TFA and desalted using GL-Tip SDB (GL Sciences). The
eluates were evaporated in a SpeedVac concentrator (Thermo Fisher Scientific).
LC-MS/MS analysis of the resultant peptides was performed on an EASY-
nLC 1200 UHPLC connected to a Q Exactive Plus mass spectrometer through a
nanoelectrospray ion source (Thermo Fisher Scientific). The peptides were
separated on a 75-μm inner diameter × 150 mm C18 reversed-phase column
(Nikkyo Technos) with a linear gradient from 4 to 28% acetonitrile (ACN) for
0–100 min followed by an increase to 80% ACN during 100–110 min. The mass
spectrometer was operated in a data-dependent acquisition mode with a top 10
MS/MS method. MS1 spectra were measured with a resolution of 70,000, an AGC
target of 1 × 106 and a mass range from 350 to 1,500 m/z. MS/MS spectra were
triggered at a resolution of 17,500, an AGC target of 5 × 104, an isolation window
of 2.0m/z, a maximum injection time of 60 ms, and a normalized collision energy
of 27. Dynamic exclusion was set to 10 s. Raw data were directly analyzed against
the SwissProt database restricted to Rattus using Proteome Discoverer version 2.2
(Thermo Fisher Scientific) for identification and label-free precursor ion quanti-
fication. The search parameters were as follows: (i) trypsin as an enzyme with up
to one missed cleavage; (ii) precursor mass tolerance of 10 ppm; (iii) fragment
mass tolerance of 0.02 Da; (iv) carbamidomethylation of cysteine as a fixed
modification; and (v) oxidation of methionine and phosphorylation of serine,
threonine, and tyrosine as variable modifications. Peptides were filtered at a
false-discovery rate of 1% using the percolator node. Normalization was
performed such that the total sum of abundance values for each sample over
all peptides was the same. The MS proteomics data have been deposited in
the ProteomeXchange Consortium via the jPOST partner repository (https://
repository.jpostdb.org) with the dataset identifier PXD010790 (42).
Several selected peptides, including FGFR1 with phosphorylated tyrosine
residues, were measured by PRM, an MS/MS-based targeted quantification
method using high-resolution MS. Targeted MS/MS scans were acquired by a
time-scheduled inclusion list at a resolution of 70,000, an AGC target of 2 × 105,
an isolation window of 4.0 m/z, a maximum injection time of 500 ms, and a
normalized collision energy of 27. Time alignment and relative quantification
of the transitions were performed with PinPoint version 1.4 (Thermo Fisher
Scientific). The MS proteomics data for PRM analysis have been deposited in
the ProteomeXchange Consortium via the jPOST partner repository with the
dataset identifier PXD010791.
Analysis of mRNA Stability. The analytical method was previously described
(43). Galnt3 mRNA levels in UMR106 cells were analyzed by RT-qPCR at 0, 1,
2, and 4 h after treatment with actinomycin D. The half-life of the mRNA
was calculated by a method previously described.
Statistics.All data are presented as themean± SEM. The results were analyzed for
significant differences using Student’s t test or ANOVA followed by a Dunnett’s
or Tukey’s multiple comparison post hoc test. Significance was set at P < 0.05.
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